The diagnosis of pancreatic cancer confers a grim prognosis that has changed little over the last 30 years. Due to the lack of any efficacious screening or biomarkers for pancreatic cancer, presentation with advanced local disease is typical (classically, painless jaundice) and morbidity aside, 4% of patients are alive 5 years after the time of diagnosis. The nucleoside analogue gemcitabine, wh...
